Education
About Us
Working with TipRanks
Follow Us
Achilles Therapeutics (DE:698)
MUNICH:698
RESEARCH TOOLSreports
698 Stock Chart & Stats
Day’s Range― - ―
52-Week Range€0.59 - €1.41
Previous CloseN/A
Volume0.00
Average Volume (3M)700.00
Market Cap
$56.32M
Enterprise ValueN/A
Total Cash (Recent Filing)$95.11M
Total Debt (Recent Filing)$4.46M
Price to Earnings (P/E)―
Beta0.69
Next Earnings
May 13, 2025EPS Estimate
-0.35Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding41,087,902
10 Day Avg. Volume0
30 Day Avg. Volume700
Financial Highlights & Ratios
PEG Ratio0.24
Price to Book (P/B)0.58
Price to Sales (P/S)N/A
P/FCF Ratio-1.93
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Achilles Therapeutics News
PremiumCompany Announcements
Achilles Therapeutics Announces Voluntary Liquidation and Delisting
PremiumCompany Announcements
Achilles Therapeutics to Delist from Nasdaq and Deregister with SEC
PremiumCompany Announcements
Achilles Therapeutics Proposes Voluntary Liquidation to Return Capital
PremiumCompany Announcements
Achilles Therapeutics Announces Board Resignations Amid Strategic RealignmentOptions Prices
Currently, No data available
---
Ownership Overview
―
Insiders
0.05%
Mutual Funds
― Other Institutional Investors
99.95% Public Companies and
Individual Investors
698 FAQ
What was Achilles Therapeutics’s price range in the past 12 months?
Achilles Therapeutics lowest stock price was €0.59 and its highest was €1.41 in the past 12 months.
What is Achilles Therapeutics’s market cap?
Achilles Therapeutics’s market cap is $56.32M.
When is Achilles Therapeutics’s upcoming earnings report date?
Achilles Therapeutics’s upcoming earnings report date is May 13, 2025 which is 32 days ago.
How were Achilles Therapeutics’s earnings last quarter?
Currently, no data Available
Is Achilles Therapeutics overvalued?
According to Wall Street analysts Achilles Therapeutics’s price is currently Overvalued.
Does Achilles Therapeutics pay dividends?
Achilles Therapeutics does not currently pay dividends.
What is Achilles Therapeutics’s EPS estimate?
Achilles Therapeutics’s EPS estimate is -0.35.
How many shares outstanding does Achilles Therapeutics have?
Achilles Therapeutics has 41,087,902 shares outstanding.
What happened to Achilles Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Achilles Therapeutics?
Currently, no hedge funds are holding shares in DE:698
Achilles Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
―
20 days / 200 days
Momentum
14.72%
12-Months-Change
Fundamentals
Return on Equity
-52.41%
Trailing 12-Months
Asset Growth
-30.03%
Trailing 12-Months
Company Description
Achilles Therapeutics
Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. It is also developing products for use in the treatment of head and neck squamous cell carcinoma, renal cell carcinoma, triple negative breast cancer, and bladder cancer. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. The company was founded in 2016 and is headquartered in London, the United Kingdom.
Technical Analysis
Fate Therapeutics
―
Karyopharm Therapeutics
―
Iovance Biotherapeutics
―
Adaptimmune Therapeutics
―
Immatics
―